Show simple item record

dc.contributor.authorSinghal, Tarunen_US
dc.contributor.authorTauhid, Shahamaten_US
dc.contributor.authorHurwitz, Shelleyen_US
dc.contributor.authorNeema, Mohiten_US
dc.contributor.authorBakshi, Rohiten_US
dc.date.accessioned2017-03-28T23:49:29Z
dc.date.issued2016en_US
dc.identifier.citationSinghal, Tarun, Shahamat Tauhid, Shelley Hurwitz, Mohit Neema, and Rohit Bakshi. 2016. “The Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosis.” Journal of Neuroimaging 27 (1): 33-36. doi:10.1111/jon.12378. http://dx.doi.org/10.1111/jon.12378.en
dc.identifier.issnen
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:31731741
dc.description.abstractABSTRACT BACKGROUND Spinal cord atrophy occurs early in the multiple sclerosis (MS) disease course, is closely related to physical disability, and is a putative neuroprotective therapeutic outcome measure. OBJECTIVE This pilot study explored glatiramer acetate (GA)’s effect on spinal cord volume in patients with relapsing‐remitting MS (RRMS). METHODS Fifteen patients receiving daily subcutaneous GA were prospectively followed. At baseline, age was 43.6 ± 7.4 years, Expanded Disability Status Scale (EDSS) score was 1.4 ± 1.5, timed 25‐foot walk (T25FW) was 4.7 ± 1.1 seconds, and time on GA was 2.1 ± 3.1 years. Healthy controls (n = 10) with similar age and sex to the patients were also enrolled. The spinal cord was imaged at baseline and one year later with 3T magnetic resonance imaging. An active surface method measured the C1–C7 spinal cord volume from which we calculated the normalized area. RESULTS The spinal cord area showed no significant change in the MS group over one year (P = .19). Furthermore, the change in the spinal cord area did not differ significantly between the MS and control groups over one year (P = .26). In the MS group, the EDSS score (P = .44) and T25FW (P = .92) did not change significantly on‐study. CONCLUSION In this pilot study of RRMS, GA therapy was not associated with any ongoing spinal cord atrophy or any difference in the one‐year rate of spinal cord area change versus healthy controls. These results paralleled the lack of clinical worsening and may reflect a treatment effect of GA. Further studies are needed to confirm these preliminary findings.en
dc.language.isoen_USen
dc.publisherJohn Wiley and Sons Inc.en
dc.relation.isversionofdoi:10.1111/jon.12378en
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC5248648/pdf/en
dash.licenseLAAen_US
dc.subjectShort Communicationen
dc.subjectMRIen
dc.subjectmultiple sclerosisen
dc.subjectglatiramer acetateen
dc.subjectspinal cord atrophyen
dc.titleThe Effect of Glatiramer Acetate on Spinal Cord Volume in Relapsing‐Remitting Multiple Sclerosisen
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden
dc.relation.journalJournal of Neuroimagingen
dash.depositing.authorSinghal, Tarunen_US
dc.date.available2017-03-28T23:49:29Z
dc.identifier.doi10.1111/jon.12378*
dash.contributor.affiliatedSinghal, Tarun
dash.contributor.affiliatedHurwitz, Shelley
dash.contributor.affiliatedTauhid, Shahamat
dash.contributor.affiliatedBakshi, Rohit


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record